Treatments:
Safety and Efficacy of Anlotinib Hydrochloride Plus Temozolomide in Patients with Recurrent Glioblastoma. Glioblastoma (GBM) is a highly vascularised tumour with few treatment options after disease recurrence. In this study, researchers report that Anlotinib hydrochloride combined with temozolomide is efficacious and tolerated in patients with recurrent GBM. Full study results are published in Clinical Cancer Research and are behind a paywall if you don’t have a subscription.
Dose Escalated Radiotherapy is Associated with Improved Outcomes for High Grade Meningioma. In this study, researchers investigated the optimal radiotherapy approach after surgery for atypical and malignant meningioma. Published in International Journal of Radiation Oncology, researchers present the results of dose-escalation radiotherapy in a single institution cohort spanning 2000-2021 for histopathologic grade 2 or 3 meningioma. They found that dose-escalated radiotherapy with ≥66Gy for high grade meningioma is associated with improved local control and progression free survival with an acceptable risk of radiation necrosis.
Biodexa Completes Recruitment of Cohort A in Study of MTX110 in Patients with Recurrent Glioblastoma. Biodexa Pharmaceuticals PLC has announced that it has completed recruitment into cohort A of its ongoing Phase 1 study of MTX110 (also known as MAGIC-G1 study) (NCT 05324501) in patients with recurrent glioblastoma (rGBM).
MAGIC-G1 is an open-label, dose escalation study designed to assess the feasibility and safety of intermittent infusions of MTX110 administered by convection enhanced delivery (CED) via implanted refillable pump and catheter. MTX110 is a liquid formulation of the histone deacetylase (HDAC) inhibitor, panobinostat. This proprietary formulation enables delivery of the product via convection-enhanced delivery (CED) at potentially therapeutic doses directly to the site of the tumour, by-passing the blood-brain barrier and avoiding systemic toxicity.
Research:
Predicting survival in glioblastoma with multimodal neuroimaging and machine learning. In this study, researchers report that machine learning can accurately classify survival in glioblastoma (GBM) patients based on multimodal neuroimaging before any surgical or medical intervention. Published in the Journal of Neuro-Oncology, these results were achieved from structural neuroimaging and resting state functional MRI before surgery. The ability to predict survival before treatment in GBM patients would lead to improved disease management, clinical trial enrolment, and patient care
Review:
Our changing approach to rare cancers is driving progress, but we still have further to go. To mark Rare Cancer Day, Isy Godfrey at The Institute of Cancer Research looks at how they are making progress in this field and speaks with paediatric brain tumour expert Professor Chris Jones, Director of the Brain Tumour Research Centre of Excellence at The Institute of Cancer Research, Sutton, about his experiences.